Perioral Dermatitis Treatment: Steroid-Triggered Face Rash and What Actually Clears It

Perioral dermatitis—more accurately designated periorificial dermatitis (POD) when it extends beyond the perioral zone to encompass the perinasal, periocular, or vulvar mucocutaneous junctions—is a chronic, papulopustular inflammatory dermatosis. Characterized by small, erythematous papules, microvesicles, and pustules resting on a background of patchy mild erythema, POD classically displays a pathognomonic sparing of the narrow 1 to 2 mm vermilion border of the lips. The condition predominantly affects adult females between the ages of 20 and 45, though pediatric periorificial dermatitis is increasingly recognized in children following topically or inhalationally administered corticosteroids (StatPearls NBK525968).

Despite its frequency in outpatient dermatology, perioral dermatitis remains one of the most frequently misdiagnosed and mistreated facial eruptions. Patients routinely mistake the early micro-papules and fine scaling for dry skin, localized eczema, or contact allergy, prompting the self-application of over-the-counter hydrocortisone or heavy occlusive moisturizers. This initiates a damaging physiological cycle: topical corticosteroids exert rapid local anti-inflammatory and vasoconstrictive effects that temporarily blunt redness for 24 to 48 hours, followed by an aggressive, rebound inflammatory flare upon discontinuation. Driven by panic, patients reapply the steroid—often stepping up to higher-potency fluorinated molecules like triamcinolone, betamethasone, or clobetasol—creating a severe steroid-addicted dermatosis.

This evidence-based clinical guide analyzes the pathophysiological triggers of perioral dermatitis, establishes a safe corticosteroid tapering and withdrawal protocol, evaluates zero therapy versus prescription topical agents (metronidazole, pimecrolimus, azelaic acid), defines clinical thresholds for systemic antibiotic escalation (doxycycline, tetracycline, erythromycin), addresses pediatric and granulomatous variants, and provides a clear differential diagnostic framework comparing POD to rosacea, acne vulgaris, and seborrheic dermatitis.

---

Direct Answer: How Perioral Dermatitis Is Treated

If you have developed a bumpy, burning red eruption around your mouth, nose, or eyelids, clearing it requires a disciplined, evidence-based ladder approach:

1. Immediate Corticosteroid Cessation (Steroid Tapering Protocol): You must stop applying all topical, inhaled, or nasal corticosteroids to the face. If high-potency topical steroids have been used for more than two weeks, abrupt withdrawal produces an intense, painful rebound flare. You must execute a structured 1-to-2-week step-down taper (substituting OTC 1% hydrocortisone temporarily, then bridging with topical pimecrolimus) while expecting temporary inflammatory worsening.
2. Enforce "Zero Therapy" (Null Regimen): Immediately discontinue all cosmetic face creams, anti-aging serums, heavy foundations, liquid concealers, physical sunscreens, physical scrubs, fluorinated toothpastes, and multi-step skincare routines. Cleanse the face exclusively with lukewarm water or a minimal, non-soap liquid cleanser twice daily.
3. First-Line Prescription Topical Therapy:
   • Topical Metronidazole (0.75%–1% cream or gel): Applied in a thin layer twice daily for 4 to 8 weeks to suppress follicular inflammatory cascades.
   • Topical Pimecrolimus (1% Elidel cream): Applied twice daily for 2 to 4 weeks. Highly effective for steroid-induced rebound flares due to its non-steroidal calcineurin-inhibitor mechanism, though patients must be counseled regarding off-label use and its FDA black-box warning.
   • Topical Azelaic Acid (15%–20%): Provides anti-inflammatory and keratolytic benefits, particularly useful in pregnant patients, though recent systematic reviews demonstrate mixed acute clearance efficacy compared to metronidazole.
4. Systemic Antibiotic Escalation (Moderate, Severe, or Granulomatous Cases): For extensive papulopustular eruptions or severe post-steroid flares, oral doxycycline (50–100 mg twice daily for 4 to 8 weeks) or sub-antimicrobial doxycycline (40 mg modified-release daily) is the treatment of choice. Antibiotics function in POD via anti-inflammatory enzyme inhibition rather than bactericidal destruction.
5. Expected Clinical Timeline: Complete resolution requires 4 to 12 weeks. Recurrence rates are exceptionally low provided steroid exposure and heavy cosmetic occlusive habits are permanently eliminated.

---

Pathophysiology and Environmental Triggers

The development of perioral dermatitis involves a complex interplay between epidermal barrier disruption, follicular micro-occlusion, altered stratum corneum lipid composition, and dysbiosis of the follicular microflora.

          ┌─────────────────────────────────────────────────────────────┐
          │             PRIMARY INCITING EXOGENOUS TRIGGERS             │
          ├──────────────────────────────┬──────────────────────────────┤
          │ Topical/Inhaled Steroids     │ Heavy Layered Cosmetics      │
          │ Fluorinated Toothpastes      │ Sunscreen Micro-Occlusion    │
          └──────────────────────────────┬──────────────────────────────┘
                                         │
                                         ▼
          ┌─────────────────────────────────────────────────────────────┐
          │     STRATUM CORNEUM DISRUPTION & FOLLICULAR MICRO-OCCLUSION  │
          └──────────────────────────────┬──────────────────────────────┘
                                         │
                                         ▼
          ┌─────────────────────────────────────────────────────────────┐
          │       PERIORIFICIAL ERYTHEMA & PAPULOPUSTULAR ERUPTION       │
          │             (SPARING VERMILION BORDER OF LIPS)              │
          └──────────────────────────────┬──────────────────────────────┘
                                         │
                    ┌────────────────────┴────────────────────┐
                    ▼                                         ▼
    ┌───────────────────────────────┐         ┌───────────────────────────────┐
    │     MILD TO MODERATE POD      │         │   SEVERE / STEROID-REBOUND POD│
    └───────────────┬───────────────┘         └───────────────┬───────────────┘
                    │                                         │
                    ▼                                         ▼
    ┌───────────────────────────────┐         ┌───────────────────────────────┐
    │ Zero Therapy + Topical        │         │ Steroid Taper + Oral          │
    │ Metronidazole / Pimecrolimus  │         │ Doxycycline (50-100mg BID)    │
    └───────────────┬───────────────┘         └───────────────┬───────────────┘
                    │                                         │
                    └────────────────────┬────────────────────┘
                                         │
                                         ▼
    ┌─────────────────────────────────────────────────────────────────────────┐
    │     Complete Clinical Resolution (Expected Timeline: 4 to 12 Weeks)    │
    └─────────────────────────────────────────────────────────────────────────┘

The Steroid-Rebound Mechanism

Topical corticosteroid exposure is the most potent and well-characterized trigger of severe POD. Steroids alter cutaneous physiology through three key pathways:

1. Local Immunosuppression: Corticosteroids suppress local T-lymphocyte surveillance and downregulate pro-inflammatory cytokines, allowing commensal follicular microorganisms (Fusobacterium species, Candida albicans, and Demodex folliculorum mites) to proliferate unchecked inside hair follicles.
2. Epidermal Barrier Degradation: Prolonged topical steroid application inhibits lipid synthesis in epidermal keratinocytes, diminishing intercellular ceramide levels, accelerating transepidermal water loss (TEWL), and causing stratum corneum atrophy.
3. Rebound Vasodilation: Upon steroid discontinuation, local capillary receptors upregulate pro-inflammatory mediators. The sudden influx of neutrophils and T-cells into the compromised hair follicles results in painful, burning papules, pustules, and severe swelling within 48 to 72 hours.

Inhaled corticosteroids used for asthma management and nasal steroid sprays used for allergic rhinitis routinely leak around mask edges or deposit near nostrils, creating perinasal POD.

Cutaneous Barrier Lipid Depletion and Recovery Kinetics

Histological and biophysical measurements of stratum corneum function in patients with perioral dermatitis show marked alterations in skin surface lipids and barrier permeability:

• Transepidermal Water Loss (TEWL): Baseline TEWL values in active POD lesions are significantly elevated (often exceeding 25 to 35 g/m²/h compared to normal facial values of 10 to 15 g/m²/h), reflecting severe stratum corneum dysfunction.
• Intercellular Lipid Ratios: Normal skin barrier integrity requires a balanced equimolar ratio of ceramides, free fatty acids, and cholesterol (1:1:1 ratio). Prolonged steroid exposure or heavy cosmetic micro-occlusion disrupts ceramide synthesis, leading to localized depletion of ceramides 1 and 3.
• Barrier Recovery Kinetics: Following complete cessation of cosmetics and corticosteroids, natural keratinocyte lipid synthesis requires approximately 14 to 28 days to rebuild intercellular lamellar membranes. Applying active retinoids or chemical acids during this fragile recovery phase disrupts newly forming lipid bilayers and triggers acute relapse.

Cosmetic Micro-Occlusion and the Malik 2000 Study

Non-steroid POD is frequently induced by cosmetic layering. Rich night creams, thick liquid foundations, physical zinc oxide sunscreens, and heavy facial oils create a physical barrier that traps sebum and cellular debris within the pilosebaceous infundibulum.

A classic case-control study by Malik and Quirk (2000, published in Australas J Dermatol, PMID 10715898) investigated topical application habits among women with perioral dermatitis. Their multivariate statistical analysis yielded striking findings:

• Combined application of a liquid foundation, a day moisturizer, and a night cream resulted in a 13-fold increased risk (OR = 13.5, p < 0.001) of developing perioral dermatitis compared to minimal product users.
• Single-product use carried significantly lower odds ratios, proving that multi-step product layering is the primary cosmetic driver of follicular micro-occlusion.
• Fluorinated toothpaste formulations, sodium lauryl sulfate (SLS) surfactants, and heavy paraffin cosmetics were identified as secondary contact irritants capable of initiating micro-papular eruptions around the mouth.

---

The Zero Therapy Protocol and Safe Steroid Tapering

Successful clearance of perioral dermatitis begins not with adding new medications, but with eliminating environmental triggers and managing corticosteroid withdrawal.

What Is "Zero Therapy" (Null Therapy)?

Zero therapy represents the complete cessation of all topical cosmetic products, skincare formulations, and active ingredients applied to the face:

• Strict Discontinuation List: All anti-aging creams, retinoids, L-ascorbic acid serums, chemical exfoliants (AHAs/BHAs), facial oils, heavy moisturizers, liquid foundations, concealers, physical sunscreens, physical cleansing brushes, and over-the-counter hydrocortisone creams.
• Permitted Hygiene Routine: Cleanse the face twice daily using only lukewarm water or a minimal, non-soap, fragrance-free liquid cleanser (such as Cetaphil Gentle Skin Cleanser or CeraVe Hydrating Cleanser). Gently pat dry with a clean cotton towel.
• Physiological Rationale: Removing exogenous occlusive lipids allows the stratum corneum to restore natural ceramide-cholesterol lipid ratios, lowers transepidermal water loss, and normalizes follicular microflora equilibrium. Clinical trial data shows that zero therapy alone achieves complete resolution in 25% to 30% of mild POD cases, though patients must be prepared for a 4-to-8-week healing timeline.

Corticosteroid Tapering Protocols

Abruptly stopping topical facial steroids after weeks of continuous use induces severe rebound flares that cause immense patient distress. Dermatologists utilize a structured tapering schedule to step down steroid potency while bridging with non-steroidal anti-inflammatory topicals:

┌─────────────────────────────────────────────────────────────────────────┐
│                      STRUCTURED STEROID TAPER SCHEDULE                  │
├───────────────┬─────────────────────────────────────────────────────────┤
│ Phase 1       │ Step down from high-potency steroid (e.g., Clobetasol / │
│ (Days 1–4)    │ Triamcinolone) to OTC 1% Hydrocortisone cream once daily.│
├───────────────┼─────────────────────────────────────────────────────────┤
│ Phase 2       │ Apply 1% Hydrocortisone every other day for 4 days while│
│ (Days 5–8)    │ initiating topical Pimecrolimus 1% cream twice daily.   │
├───────────────┼─────────────────────────────────────────────────────────┤
│ Phase 3       │ Discontinue Hydrocortisone completely; continue topical │
│ (Days 9+)     │ Pimecrolimus 1% twice daily + Zero Therapy regimen.     │
└───────────────┴─────────────────────────────────────────────────────────┘

---

Topical Pharmacotherapy: Metronidazole vs Pimecrolimus vs Azelaic Acid

When zero therapy alone is insufficient after 2 weeks or when a patient presents with painful papules, topical prescription agents are introduced.

1. Topical Metronidazole (0.75% or 1%)

Metronidazole cream or gel is the historic first-line topical intervention for perioral dermatitis.

• Mechanism of Action: Inhibits neutrophil-generated free radical production and downregulates cell-mediated inflammatory cascades within the pilosebaceous unit.
• Administration Protocol: Applied as a thin layer to clean, dry skin twice daily for 6 to 8 weeks.
• Clinical Evidence: A double-blind, double-dummy RCT by Veien et al. (1991, JAAD, PMID 2007672) evaluating 108 POD patients demonstrated that 1% topical metronidazole significantly reduced papule counts from baseline (median reduction to 8% of initial count), establishing its efficacy as a safe topical anchor.

2. Topical Pimecrolimus (1% Elidel Cream)

Pimecrolimus is a lipophilic topical calcineurin inhibitor that selectively targets T-lymphocytes and mast cells.

• Clinical Utility: Pimecrolimus is the drug of choice for corticosteroid-induced perioral dermatitis, rapidly arresting rebound inflammatory flares when steroids are withdrawn without inducing secondary skin atrophy (Oppel et al., 2007, PMID 17393437).
• Administration Protocol: Applied twice daily for 2 to 4 weeks until active papules regress.
• FDA Black-Box Warning & Off-Label Status: The FDA prescribing label for Elidel (NDA 021302) contains a black-box warning (issued in 2005 and updated in 2014) regarding theoretical risks of lymphoma and skin malignancy based on high-dose systemic animal studies. Elidel's FDA-approved indication is strictly second-line short-term treatment of atopic dermatitis; its use in perioral dermatitis is off-label. Long-term human prospective cohort studies have found no evidence of increased malignancy risk with topical calcineurin inhibitors, but clinicians must provide transparent off-label counseling.

3. Topical Azelaic Acid (15%–20%)

Azelaic acid is a naturally occurring dicarboxylic acid offering anti-inflammatory, antimicrobial, and mild keratolytic properties. It is often selected for pregnant or lactating patients requiring POD therapy due to its FDA Pregnancy Category B safety profile. Patients seeking broader information on azelaic acid across facial dermatoses can review our detailed analysis of azelaic acid for rosacea and melasma (with the POD caveat).

What Does the Systematic Evidence Review Reveal? (Gray 2022 Data)

A landmark systematic review published in the Journal of the European Academy of Dermatology and Venereology (JEADV) by Gray et al. (2022, PMID 34779023)—evaluating 11 randomized clinical studies encompassing 733 participants across 7 medical databases—provided a rigorous evaluation of POD pharmacotherapy:

• Evidence Certainty: The authors determined that the overall certainty of evidence across published POD clinical trials remains low to very low due to small cohort sample sizes and methodological trial variability.
• Tetracycline Efficacy: Oral tetracycline demonstrated consistent evidence of reducing physician-assessed POD severity from day 20 onwards compared to placebo.
• Pimecrolimus Efficacy: Topical pimecrolimus 1% cream achieved modest reduction in disease severity scores at 4 weeks (mean difference -0.49, 95% CI -1.02 to 0.04, n=164).
• Azelaic Acid Caveat: Surprisingly, pooled trial data for topical azelaic acid gel showed no statistically significant difference in disease severity at 6 weeks compared to vehicle control. While azelaic acid remains a safe option in pregnancy, clinicians should recognize that it may provide less predictable acute clearance than metronidazole or pimecrolimus.

---

Systemic Antibiotic Protocols (Doxycycline & Tetracycline)

In moderate-to-severe perioral dermatitis—characterized by widespread confluent papules, pustules, severe burning, or intense post-steroid rebound—topical therapy alone is insufficient. Oral systemic antibiotics are required to achieve rapid anti-inflammatory clearance.

Anti-Inflammatory Mechanisms and Regimens

Tetracycline-class antibiotics function in POD through non-antibacterial, anti-inflammatory mechanisms: they inhibit matrix metalloproteinases (MMP-2, MMP-9), downregulate pro-inflammatory cytokines (IL-1, TNF-alpha), and suppress neutrophil chemotaxis:

• Oral Doxycycline (First-Line Standard): 50 mg to 100 mg orally twice daily for 4 to 8 weeks, followed by a step-down taper to 50 mg once daily for 2 to 4 weeks.
• Sub-Antimicrobial Doxycycline (40 mg Modified-Release): Orally once daily. Delivers anti-inflammatory plasma concentrations without selecting for antibiotic resistance or altering gut microflora.
• Oral Tetracycline: 250 mg to 500 mg orally twice daily taken on an empty stomach 1 hour before or 2 hours after meals for 4 to 8 weeks.

Sub-Antimicrobial Doxycycline (40 mg Modified-Release Mechanics)

Sub-antimicrobial dose doxycycline (40 mg once daily controlled-release formulation, Oracea) represents an important evolution in chronic facial dermatosis management.

At a 40 mg daily dose, plasma drug levels remain below the minimum inhibitory concentration (MIC) required to suppress bacterial growth. As a result, 40 mg doxycycline exerts potent anti-inflammatory effects through direct inhibition of collagenase and matrix metalloproteinase enzymes (MMP-8 and MMP-9) without inducing selection pressure for resistant bacterial strains in the cutaneous or gastrointestinal microbiome. This makes 40 mg sub-antimicrobial doxycycline an exceptionally safe long-term anti-inflammatory option for patients with recurrent perioral dermatitis who cannot tolerate standard antimicrobial doses.

Safety Boundaries and Prescribing Directives

Per official FDA prescribing labels for doxycycline and tetracycline:

1. Photosensitivity Risk: Doxycycline induces significant cutaneous photosensitivity (exaggerated sunburn responses). Patients taking doxycycline during high-UV seasons must enforce strict sun protection.
2. Esophageal Erosion Risk: Doxycycline capsules can cause acute esophageal ulceration if trapped in the esophagus. Medication must be ingested with a full glass of water while remaining upright for at least 30 minutes.

Pediatric and Granulomatous Variations

• Pediatric POD Protocols: Tetracyclines are strictly contraindicated in children under age 8 due to irreversible tooth enamel discoloration and bone growth inhibition. In pediatric perioral dermatitis, oral erythromycin or oral azithromycin administered under weight-based pediatric dosing guidelines serves as the systemic antibiotic of choice.
• Granulomatous Perioral Dermatitis: A distinct clinical variant occurring primarily in prepubertal children and dark-skinned individuals, characterized by flesh-colored, yellow-brown, or erythematous papules that exhibit epithelioid granulomas on biopsy. Granulomatous POD is uniquely refractory to topical therapy; for recalcitrant cases, dermatologists may initiate low-dose oral isotretinoin under strict specialist monitoring. Patients evaluating retinoid safety standards should review our guidance on isotretinoin and aesthetic-procedure waiting periods.

---

Differential Diagnosis: POD vs Rosacea vs Acne vs Seborrheic Dermatitis

Misdiagnosing perioral dermatitis leads to inappropriate therapies (such as applying acne benzoyl peroxide or retinoids, which severely compromise the skin barrier). The decision matrix below outlines key diagnostic parameters.

For patients evaluating broader central facial vascular redness, consult our companion subtype-by-subtype rosacea treatment guide for comprehensive diagnostic staging.

---

Step-by-Step Product Reintroduction Framework

Once perioral dermatitis has completely resolved (defined as 4 consecutive weeks with zero new papules or burning sensations), patients often ask how to safely resume skincare without triggering a relapse. Reintroduction must follow a cautious, 4-phase protocol:

┌─────────────────────────────────────────────────────────────────────────┐
│                 POST-RECOVERY PRODUCT REINTRODUCTION FRAMEWORK          │
├───────────────┬─────────────────────────────────────────────────────────┤
│ Phase 1       │ Introduce a lightweight, non-comedogenic gel-cream      │
│ (Weeks 1–2)   │ moisturizer (fragrance-free, oil-free). Patch test first.│
├───────────────┼─────────────────────────────────────────────────────────┤
│ Phase 2       │ Add a 100% mineral sunscreen (zinc oxide / titanium     │
│ (Weeks 3–4)   │ dioxide) free of heavy petrolatum or silicones.          │
├───────────────┼─────────────────────────────────────────────────────────┤
│ Phase 3       │ Reintroduce minimal mineral powder makeup; avoid heavy  │
│ (Weeks 5–6)   │ liquid foundations and thick concealer sticks.          │
├───────────────┼─────────────────────────────────────────────────────────┤
│ Phase 4       │ Cautiously reintroduce low-concentration active ingredients│
│ (Week 7+)     │ (e.g., azelaic acid 10%); permanently avoid topical     │
│               │ facial corticosteroids and 5-step cosmetic layering.    │
└───────────────┴─────────────────────────────────────────────────────────┘

---

Frequently Asked Questions

How long does perioral dermatitis take to clear completely?

With strict adherence to zero therapy and first-line topical prescription treatment (metronidazole or pimecrolimus), mild POD typically resolves within 4 to 6 weeks. Moderate-to-severe cases requiring oral doxycycline require 6 to 12 weeks for complete resolution. Applying hydrocortisone or physical scrubs in an attempt to speed up clearance will prolong the dermatosis for months.

Will perioral dermatitis return after I finish taking oral antibiotics?

Recurrence is low provided you identify and permanently eliminate your original environmental triggers. If your POD was induced by topical corticosteroid application or multi-step cosmetic layering, returning to those products will trigger a relapse. Maintain a simplified, non-comedogenic skincare routine after completing your antibiotic course.

Is pimecrolimus (Elidel) safe given the FDA black-box warning?

Yes, when prescribed by a dermatologist for short-term inflammatory management. The FDA black-box warning on Elidel was instituted in 2005 based on high-dose oral rodent studies. Extensive prospective human epidemiological studies following tens of thousands of patients over multi-year periods have shown no evidence of increased lymphoma or systemic malignancy with topical calcineurin inhibitor use. Pimecrolimus remains a critical non-steroidal tool for arresting steroid-induced rebound flares.

What should I do if my job requires wearing a tight mask daily?

Occupational mask wear (N95s, surgical masks) can trap moisture and increase follicular occlusion, aggravating POD. Change masks frequently throughout the day, avoid wearing any liquid makeup or heavy lip balms under the mask, pat the perioral skin dry during breaks, and apply a thin layer of topical metronidazole 15 minutes before putting on your mask.

Can fluorinated water or fluoride toothpaste really cause perioral dermatitis?

Fluorinated toothpastes are a well-documented contact irritant that can exacerbate perioral papules in sensitive individuals. While municipal fluorinated drinking water has not been scientifically linked to POD, switching to a fluoride-free, SLS-free toothpaste during active treatment is a standard dermatological recommendation to eliminate localized contact irritation around the mouth.

What is the difference between perioral dermatitis and granulomatous perioral dermatitis?

Classic perioral dermatitis features erythematous papules and pustules around the mouth with vermilion sparing in young adult females. Granulomatous perioral dermatitis is a distinct variant occurring predominantly in prepubertal children (and skin of color), featuring flesh-colored or yellow-brown papules that demonstrate epithelioid granulomas on skin biopsy. Granulomatous POD is more resistant to standard topicals and may require oral erythromycin or low-dose oral isotretinoin.

Can climate, humidity, or seasonal weather changes trigger perioral dermatitis flares?

Yes. High environmental humidity combined with sweat causes mild epidermal hydration expansion, increasing follicular occlusion and aggravating micro-papular flares during summer months. Conversely, cold winter winds combined with indoor heating strip stratum corneum lipids, compromising barrier function and driving patients to reapply heavy occlusive creams that precipitate POD. Maintaining a minimal, oil-free hydrating routine across all seasons minimizes climate-induced flares.

---

Sources

• StatPearls — Perioral Dermatitis (Tolaymat, Syed, Hall): https://www.ncbi.nlm.nih.gov/books/NBK525968/
• Gray et al., JEADV 2022 — Pharmacological Interventions for Periorificial Dermatitis Systematic Review (PMID 34779023): https://pubmed.ncbi.nlm.nih.gov/34779023/
• American Academy of Dermatology — Perioral Dermatitis Overview & Guidance: https://www.aad.org/public/diseases/a-z/perioral-dermatitis
• DermNet NZ — Periorificial Dermatitis Clinical Reference: https://dermnetnz.org/topics/periorificial-dermatitis
• Veien et al., JAAD 1991 — Topical Metronidazole vs Oral Tetracycline in Perioral Dermatitis (PMID 2007672): https://pubmed.ncbi.nlm.nih.gov/2007672/
• Malik & Quirk, Australas J Dermatol 2000 — Topical Applications and Perioral Dermatitis Case-Control Study (PMID 10715898): https://pubmed.ncbi.nlm.nih.gov/10715898/
• Elidel (Pimecrolimus 1%) FDA Prescribing Information & Black-Box Warning Label (NDA 021302): https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf
• Oppel et al., Cutis 2007 — Pimecrolimus Cream 1% in Steroid-Induced Perioral Dermatitis (PMID 17393437): https://pubmed.ncbi.nlm.nih.gov/17393437/